There may be 'up to 100 million doses' of a COVID-19 vaccine available by the end of the year, U.S. Secretary of Health and Human Services Alex Azar stated last week.
.
"Following our guidelines, the participant's illness is being reviewed and evaluated by the ENSEMBLE independent Data Safety Monitoring Board as well as our internal clinical and safety physicians. The protocol for phase three was also made available online"to provide additional transparency in [the] context of pandemic," Moderna said in a statement.In late September, Maryland-based biotechnology firm Novavax began phase three of its NVX-CoV2373 vaccine trial, which is being conducted in the U.K., in partnership with the British government's Vaccines Taskforce.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Johnson & Johnson pauses Covid-19 vaccine trial after 'unexplained illness'Johnson&Johnson said its Janssen arm had paused its coronavirus vaccine trial after an 'unexplained illness' in one of the volunteers testing its experimental Covid-19 shot.
Read more »
Johnson & Johnson Halt All Covid-19 Vaccine Trials Over ‘Unexplained Illness’The pause includes late-stage stage trials for the group’s single dose Covid-19 vaccine.
Read more »
Johnson & Johnson pauses clinical trials for a Covid-19 vaccine over participant's illnessJohnson & Johnson has paused its clinical trials for a Covid-19 vaccine candidate after a participant fell ill, just weeks after it announced that trials were in their final stage.
Read more »
Johnson & Johnson Pauses Covid-19 Vaccine Trials Due to Sick SubjectThe company says an independent committee is reviewing the subject’s illness, and it will review the medical information before deciding whether to restart the studies
Read more »
Johnson & Johnson pauses clinical trials for a Covid vaccine over patient illnessThe trial was paused after an “unexplained” illness in one of its participants and in compliance with regulatory standards, the company said.
Read more »